Bruker (NASDAQ:BRKR) Receives “Buy” Rating from Guggenheim

Guggenheim reissued their buy rating on shares of Bruker (NASDAQ:BRKR) in a research note published on Friday morning,Benzinga reports.

BRKR has been the topic of a number of other reports. Barclays dropped their price objective on shares of Bruker from $75.00 to $69.00 and set an “overweight” rating on the stock in a report on Wednesday, November 6th. Bank of America increased their price objective on Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a report on Friday, December 13th. Citigroup decreased their target price on Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. UBS Group assumed coverage on shares of Bruker in a report on Tuesday, December 10th. They issued a “neutral” rating and a $66.00 price target on the stock. Finally, Wolfe Research cut shares of Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. Six equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Bruker has an average rating of “Moderate Buy” and an average target price of $74.45.

Bruker Trading Down 3.6 %

Shares of NASDAQ:BRKR opened at $56.88 on Friday. The business’s 50-day moving average is $57.79 and its 200 day moving average is $61.66. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73. Bruker has a 1 year low of $48.07 and a 1 year high of $94.86. The firm has a market capitalization of $8.62 billion, a P/E ratio of 27.35, a P/E/G ratio of 3.55 and a beta of 1.17.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.61 by ($0.01). The company had revenue of $864.40 million for the quarter, compared to analyst estimates of $866.46 million. Bruker had a net margin of 9.41% and a return on equity of 21.52%. The business’s revenue was up 16.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.74 EPS. On average, research analysts predict that Bruker will post 2.39 earnings per share for the current fiscal year.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Shareholders of record on Monday, December 2nd were issued a $0.05 dividend. The ex-dividend date of this dividend was Monday, December 2nd. This represents a $0.20 dividend on an annualized basis and a yield of 0.35%. Bruker’s payout ratio is 9.62%.

Insider Transactions at Bruker

In other Bruker news, CEO Frank H. Laukien acquired 100,000 shares of the business’s stock in a transaction dated Monday, November 18th. The stock was acquired at an average cost of $50.14 per share, for a total transaction of $5,014,000.00. Following the completion of the transaction, the chief executive officer now directly owns 38,439,563 shares of the company’s stock, valued at $1,927,359,688.82. This represents a 0.26 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 28.30% of the company’s stock.

Institutional Investors Weigh In On Bruker

Institutional investors have recently added to or reduced their stakes in the stock. True Wealth Design LLC lifted its holdings in Bruker by 4,636.4% during the third quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 510 shares in the last quarter. Eagle Bay Advisors LLC raised its position in shares of Bruker by 2,324.1% during the 4th quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company’s stock worth $41,000 after purchasing an additional 674 shares during the last quarter. UMB Bank n.a. lifted its stake in Bruker by 115.3% in the 3rd quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock valued at $46,000 after buying an additional 354 shares in the last quarter. Gordian Capital Singapore Pte Ltd acquired a new stake in Bruker in the 2nd quarter worth about $52,000. Finally, GAMMA Investing LLC increased its stake in Bruker by 81.0% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock worth $60,000 after buying an additional 388 shares in the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.